Avian ("Bird") Flu Stocks Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Avian ("Bird") Flu Stocks

NNVC 1.685

+0.3%

3:55 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: lexi2004 who wrote (356)	3/19/2006 1:08:03 PM
From: javana	Read Replies (1) of 428

Hi lexi2004, look at AMBRI . Thats an australian research company. Respiratory diagnostics program at AMBRI Sydney-based Ambri Limited (ASX: ABI) today released additional detail about its recently announced program to develop a rapid diagnostic test chip for human respiratory infections including a test for avian flu infection. AMBRI has shown in a laboratory test bed system that three different assays can be performed simultaneously on its current biosensor chip configuration. The new chip configuration is on an inexpensive plastic base and fits the existing laboratory test bed reader developed by AMBRI. The common Flu A (influenza type A) was one of the tests demonstrated in the Company’s 16 sensor diagnostic test chip. AMBRI is now extending the ICS™ biosensor chip development program to include avian influenza type H5N1. The near term objective of this strategy is to develop a prototype of a chip that would be the basis of a product to simultaneously detect in a nasal or throat swab, the presence of any one of three influenza viral types. These viral infections all begin with very similar symptoms and it is important to rapidly distinguish serious infections such as Bird Flu from common influenza such as Flu A or Flu B. According to AMBRI CEO, Roman Zwolenski, “progressing down this development path with multiple yes or no tests on the same chip gives AMBRI the best chance of attracting a commercial partner to incorporate the ICS™ biosensor technology in a marketable product”. For the triple test respiratory diagnostic chip, AMBRI intends to use a new 16 sensor ICS™ configuration which AMBRI expects to be able to gold imprint and fully assemble in house. Investors are waiting for a merger........................ ; ) ambri.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next